Adynovi

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
IB/0041/G	This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.d.1.a.4 - Stability of AS - Change in the re-test	25/11/2024	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation				
IB/0042	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	11/10/2024	n/a		
PSUSA/10663 /202311	Periodic Safety Update EU Single assessment - rurioctocog alfa pegol	13/06/2024	n/a		PRAC Recommendation - maintenance
IB/0039	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	22/11/2023	n/a		
II/0036/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting	20/07/2023	n/a		

	material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS				
II/0035	Update of sections 4.4. and 4.8 of the SmPC in order to add a new warning on anaphylactic reaction and to add 'anaphylactic reaction' to the list of adverse drug reactions (ADRs) with frequency 'Not Known', based on the cumulative review of MAH global database and literature search. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the product information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	13/07/2023	30/08/2024	SmPC and PL	Cases of anaphylactic reaction have been reported, therefore sections 4.4. and 4.8 of the SmPC have been updated to add a new warning on anaphylactic reaction and to add 'anaphylactic reaction' to the list of adverse drug reactions (ADRs) with frequency 'Not Known'. Please refer to Scientific Discussion 'Adynovi-H-C-II-32'

PSUSA/10663 /202211	Periodic Safety Update EU Single assessment - rurioctocog alfa pegol	08/06/2023	n/a		PRAC Recommendation - maintenance
IB/0037	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	01/06/2023	30/08/2024	Annex II	
IA/0038	B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation	29/05/2023	n/a		
R/0033	Renewal of the marketing authorisation.	15/09/2022	09/11/2022	SmPC, Annex II and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of ADYNOVI in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
PSUSA/10663 /202111	Periodic Safety Update EU Single assessment - rurioctocog alfa pegol	10/06/2022	n/a		PRAC Recommendation - maintenance
WS/2218/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and	12/05/2022	09/11/2022	SmPC	

	biological/immunological medicinal products				
II/0030/G	This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	17/03/2022	n/a		
WS/2189	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products	24/02/2022	09/11/2022	SmPC and PL	
IA/0032/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder	04/02/2022	n/a		

	or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient				
II/0028	Update of section 4.8 of the SmPC in order to add ''Urticaria'' to the list of adverse drug reactions (ADRs) with frequency ''common''. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	13/01/2022	09/11/2022	SmPC and PL	Addition of "Urticaria'' as an Adverse Drug Reaction (ADR) with frequency ''common'' to section 4.8. in the SmPC following a review of data from completed studies by the US FDA. Currently Hypersensitivity is included in the SmPC and Urticaria is a manifestation of such, hence it does not represent an additional safety concern. For more information, please refer to the Summary of Product Characteristics.
II/0027	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	13/01/2022	n/a		
X/0018	Extension application to add a new strength of 3000 IU for RURIOCTOCOG ALFA PEGOL powder and solvent for solution for injection, for intravenous use.	11/11/2021	06/01/2022	SmPC, Labelling and	

	Annex I_2.(c) Change or addition of a new strength/potency			PL	
IB/0025	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	31/12/2021	n/a		
II/0024	B.I.b.1.e - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a specification parameter which may have a significant effect on the overall quality of the AS and/or the FP	16/12/2021	n/a		
PSUSA/10663 /202105	Periodic Safety Update EU Single assessment - rurioctocog alfa pegol	02/12/2021	n/a		PRAC Recommendation - maintenance
II/0022/G	This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a	11/11/2021	n/a		

	biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate				
II/0021/G	This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS	16/09/2021	06/01/2022	SmPC	
PSUSA/10663 /202011	Periodic Safety Update EU Single assessment - rurioctocog alfa pegol	10/06/2021	n/a		PRAC Recommendation - maintenance
II/0020	B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the AS	22/04/2021	n/a		

II/0017	Update of sections 4.8 and 5.1 of the SmPC resulting from further analyses of the continuation study 261302 and the pharmacokinetics-guided dosing study 261303. The Package Leaflet has been updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the Excipients guideline (sodium statement in 4.4) and the FVIII guideline (traceability statement in 4.4) and QRD template (labelling). The requested variation proposed amendments to the Summary of Product Characteristics, Labelling and Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	09/04/2021	06/01/2022	SmPC, Labelling and PL	Section 4.8 and 5.1 of the SmPC have been updated to reflect the data from study 261302 and the PK-guided dosing study 261303, several adverse reactions are added to the table e.g. ocular hyperaemia, drug eruption. In addition, the narrative on immunogenicity in the paragraph on the description of selected adverse events was updated. The package leaflet and the RMP have been updated accordingly. Please refer to Scientific Discussion 'Product Name-H-C-Product Number-II-Var.No' For more information, please refer to the Summary of Product Characteristics.
PSUSA/10663 /202005	Periodic Safety Update EU Single assessment - rurioctocog alfa pegol	26/11/2020	n/a		PRAC Recommendation - maintenance
II/0013	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	26/11/2020	n/a		
II/0015/G	This was an application for a group of variations. B.II.c.1.d - Change in the specification parameters and/or limits of an excipient - Change outside the approved specifications limits range B.II.c.1.d - Change in the specification parameters and/or limits of an excipient - Change outside the approved specifications limits range	24/09/2020	n/a		

II/0014/G	This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	17/09/2020	n/a		
PSUSA/10663 /201911	Periodic Safety Update EU Single assessment - rurioctocog alfa pegol	11/06/2020	n/a		PRAC Recommendation - maintenance
IB/0012	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	25/05/2020	n/a		
WS/1723	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.	26/03/2020	n/a		

	B.I.c.z - Container closure system of the AS - Other variation				
IB/0011	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	20/03/2020	n/a		
PSUSA/10663 /201905	Periodic Safety Update EU Single assessment - rurioctocog alfa pegol	28/11/2019	n/a		PRAC Recommendation - maintenance
WS/1634	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB	12/09/2019	n/a		
WS/1657	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	04/07/2019	n/a		
PSUSA/10663 /201811	Periodic Safety Update EU Single assessment - rurioctocog alfa pegol	14/06/2019	n/a		PRAC Recommendation - maintenance

II/0003	Update of section 5.1 of the SmPC to revise information on perioperative management including the number of surgical procedures managed with the use of Adynovi, as well as dosing and haemostatic efficacy, based on the results from the final clinical study report for the surgery study 261204. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	17/01/2019	25/03/2019	SmPC	The new data from the amended surgery study 261204 support the previous available data, both in terms of efficacy and in terms of safety. For more detailed information, please refer to the Summary of Product Characteristics.
IB/0004/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.f.1.e - Stability of FP - Change to an approved stability protocol	04/01/2019	n/a		
PSUSA/10663 /201805	Periodic Safety Update EU Single assessment - rurioctocog alfa pegol	29/11/2018	n/a		PRAC Recommendation - maintenance

IB/0001	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	12/03/2018	25/03/2019	SmPC, Annex II and PL	